生物制剂治疗川崎病的进展

摘要

川崎病（KD）是一种由全身血管炎症病变引发的儿童急性发热出疹性疾病，近年来发病率呈现出增加的趋势。传统治疗方法部分患儿效果不佳，且并发症发生率较高。因此选择合适的KD治疗方案，是当前迫切需要解决的问题。随着生物医学及药物学地不断发展，各种生物制剂应运而生，临床上逐渐用新型生物制剂代替传统的治疗方法，已取得了较为理想的效果。文章综述几种常见的生物制剂在KD临床治疗中的应用进展，旨在为KD有效治疗提供新的参考。%Kawasaki disease (KD) is a systemic vascular inflammatory lesion in children with acute febrile rash illness. The inci-dence rate in recent years is increasing. The traditional treatment in some patients is ineffective, and KD has high incidence of cardiovas-cular complications. Therefore, the selection of an appropriate therapy for KD is an urgent. With the continuous advance of biomedical and pharmacologically research, many biological agents were developed. The traditional treatment has been gradually replaced by the new biological agents which achieved the desired results. Thus this paper reviewed several common biological agents in the clinical treatment of KD.